Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Stopped early · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumor

In brief

A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors

Key facts

Study ID

NCT05255484

Run by

LaNova Medicines Limited

People needed

24

Starts

2022-05-26

Expected to finish

2023-10-06

Last updated by the study team

2023-10-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Ocala Oncology Center — Ocala, Florida, United States
• Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana, United States
• Gabrail Cancer and Research Center — Canton, Ohio, United States
• The Christ Hospital — Cincinnati, Ohio, United States
• University of Oklahoma — Norman, Oklahoma, United States
• Mary Crowley Cancer Research — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.